PT - JOURNAL ARTICLE AU - Sudre, Carole H. AU - Antonelli, Michela AU - Cheetham, Nathan J AU - Molteni, Erika AU - Canas, Liane S AU - Bowyer, Vicky AU - Murray, Ben AU - Rjoob, Khaled AU - Modat, Marc AU - Pujol, Joan Capdevila AU - Hu, Christina AU - Wolf, Jonathan AU - Spector, Tim D AU - Hammers, Alexander AU - Steves, Claire J AU - Ourselin, Sebastien AU - Duncan, Emma L TI - Symptom experience before vs. after confirmed SARS-CoV-2 infection: a population and case control study using prospectively recorded symptom data AID - 10.1101/2023.08.30.23294821 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.30.23294821 4099 - http://medrxiv.org/content/early/2023/09/01/2023.08.30.23294821.short 4100 - http://medrxiv.org/content/early/2023/09/01/2023.08.30.23294821.full AB - Background Some individuals experience prolonged illness after acute COVID-19. We assessed whether pre-infection symptoms affected post-COVID illness duration.Methods Survival analysis was performed in adults (n=23,452) with community-managed SARC-CoV-2 infection prospectively self-logging data through the ZOE COVID Symptom Study app, at least weekly, from 8 weeks before to 12 weeks after COVID-19 onset, conditioned on presence vs. absence of baseline symptoms (4-8 weeks before COVID-19). A case-control study was performed in 1350 individuals with long illness (≥8 weeks, 906 [67.1%] with illness ≥12 weeks), matched 1:1 (for age, sex, body mass index, testing week, prior infection, vaccination, smoking, index of multiple deprivation) with 1350 individuals with short illness (<4 weeks). Baseline symptoms were compared between the two groups; and against post-COVID symptoms.Findings Individuals reporting baseline symptoms had longer post-COVID symptom duration (from 10 to 15 days) with baseline fatigue nearly doubling duration. Two-thirds (910 of 1350 [67.4%]) of individuals with long illness were asymptomatic beforehand. However, 440 (32.6%) had baseline symptoms, vs. 255 (18.9%) of 1350 individuals with short illness (p<0.0001). Baseline symptoms increased the odds ratio for long illness (2.14 [CI: 1.78; 2.57]). Prior comorbidities were more common in individuals with long vs. short illness. In individuals with long illness, baseline symptomatic (vs. asymptomatic) individuals were more likely to be female, younger, and have prior comorbidities; and baseline and post-acute symptoms and symptom burden correlated strongly.Interpretation Individuals experiencing symptoms before COVID-19 have longer illness duration and increased odds of long illness. However, many individuals with long illness are well before SARS-CoV-2 infection.Competing Interest StatementTim Spector and Jonathan Wolf are co-founders and founder shareholders of ZOE Ltd. Christina Hu, and Joan Capdevila Pujol are employees of ZOE Ltd. Claire J Steves and Sebastien Ourselin have consulted for ZOE Ltd. All other authors (CHS, EM, LSC, NJC, AH, ELD, HVB, KR) declare no conflict of interest.Funding StatementThis work is supported by the Wellcome Engineering and Physical Sciences Research Council Centre for Medical Engineering at King's College London (WT 203148/Z/16/Z), the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare, and the UK Department of Health and Social Care, including the National Institute for Health Research (NIHR)- funded BioResource, Clinical Research Facility and comprehensive Biomedical Research Centre (BRC) award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust. This research was also funded in part by the Wellcome Trust grant [215010/Z/18/Z]. Investigators also received support from the Chronic Disease Research Foundation (CDRF), HMT/UKRI/MRC COVID-19 Longitudinal Health and Wellbeing - National Core Study (LHW-NCS) (MC_PC_20030, MC_PC_20059 and NIHR COV-LT-0009), Medical Research Council (MRC), British Heart Foundation (BHF), Alzheimer's Society, European Union. ZOE Limited provided in-kind support for all aspects of building, running, and supporting the app and service to users worldwide. SO was supported by the French government, through the 3IA Cote d'Azur Investments in the Future project managed by the National Research Agency (ANR) with the reference number ANR-19-P3IA-0002. EM received funds from the Medical Research Council UK (Skills Development Scheme) and from the National Institute for Health Research UK (grant n.134293).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:KCL ethics committee REMAS no. 18210, review reference LRS-19/20-18210I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData collected in the COVID Symptom Study smartphone app can be shared with other health researchers through the UK National Health Service-funded Health Data Research UK and Secure Anonymised Information Linkage consortium, housed in the UK Secure Research Platform (Swansea, UK). Anonymised data are available to be shared with researchers according to their protocols in the public interest https://web.www.healthdatagateway.org/dataset/594cfe55-96e3-45ff-874c-2c0006eeb881.